百济神州预计2025年经营利润为正;阿斯利康与宜联生物达成合作|医药早参

每日经济新闻
15 Jan

每经记者:陈星每经编辑:董兴生| 2025年1月15日 星期三 |NO.1 百济神州预计2025年全年经营利润为正1月14日,百济神州发布公告,公司首席执行官欧雷强在第43届摩根大通年度医疗健康大会上表示,公司预计将实现2025年全年经营利润为正(即营业收入大于营业成本、销售费用、管理费用及研发费用之总和)。点评:百济神州预计将实现2025年全年经营利润为正,离不开主力产品泽布替尼持续放量的贡献。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10